EUVIMEDEUVIMED entdecken
Crossref

Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification

Joseph T Rabban, Rebecca J Wolsky, Neslihan Kayraklioglu, Kurtis D Davies, Dara L Aisner, W Patrick Devine

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2026.101005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Joseph T Rabban und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of California, San Francisco, California. Electronic address: Joseph.rabban@ucsf.edu. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Tumor Suppressor Protein p53, Biomarkers, Tumor, DNA Copy Number Variations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancers with the Cancer Genome Atlas (TCGA) molecular profile of TP53-mutated, POLE-wild-type, and microsatellite-stable generally exhibit a high burden of copy number (CN) alterations and carry an increased risk for adverse outcomes, meriting maximal adjuvant therapy. In contrast, the prognosis associated with a TP53 mutation that coexists with a POLE mutation or microsatellite instability aligns with that of ultramutated or hypermutated cancers, respectively. In this study, we characterized a rare molecular subclass of endometrial cancers defined by TP53 mutation but low burden of CN alterations, wild-type p53 immunoexpression (immunohistochemistry [IHC]), and low TP53 variant allele frequency (median 13% and maximum 47%). Among 723 consecutive endometrial cancers prospectively classified using next-generation sequencing, 16 (2.2%) were CN-low/TP53-mutated/p53 wild-type IHC. Two additional cases were identified in a separate retrospective cohort of 32 recurrent low-grade early-stage endometrial cancers, bringing the total to 18 cases. They affected postmenopausal patients, exhibited low-grade endometrioid histotype, and were mostly confined to the uterus without lymphovascular space invasion. The recurrence rate was 6.25% (1/16) in the prospective cohort, and none died, placing their prognosis closer to that of CN-low than CN-high cancers. We conclude that next-generation sequencing-based TCGA classification of TP53-mutated, POLE-wild-type, microsatellite-stable endometrial cancers with TP53 variant allele frequency < 50% requires further evaluation using CN analysis and/or p53 IHC to detect this rare molecular category. IHC-based TCGA classification, such as the ProMisE protocol, will not be able to detect these cases because the p53 IHC pattern is wild-type and there are no distinguishing morphological features; this may be of relevance for analyzing ProMisE protocol-based clinical trials and outcomes studies. Long-term outcome studies are needed to refine risk stratification and treatment decisions for this unique molecular class of endometrial cancers that further contributes to the evolving understanding that the clinical significance of TP53 mutation in endometrial cancer is complex and depends on coexisting molecular alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsTumor Suppressor Protein p53Biomarkers, TumorDNA Copy Number VariationsHumansFemaleHigh-Throughput Nucleotide SequencingMutationImmunohistochemistryMiddle AgedRisk AssessmentAgedAged, 80 and overRetrospective StudiesAdult

Stichwörter der Autor:innen

TP53endometrial cancermolecular classification

Substanzen

Tumor Suppressor Protein p53TP53 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, University of California, San Francisco, California. Electronic address: Joseph.rabban@ucsf.edu.
  • Department of Pathology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado.
  • Department of Pathology, University of California, San Francisco, California.
  • Department of Pathology, University of California, San Francisco, California; Clinical Cancer Genomic Laboratory, University of California, San Francisco, California.

Zitieren

APA

Rabban, J. T., Wolsky, R. J., Kayraklioglu, N., Davies, K. D., Aisner, D. L., & Devine, W. P. (2026). Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification. Modern Pathology. https://doi.org/10.1016/j.modpat.2026.101005

Vancouver

Rabban JT, Wolsky RJ, Kayraklioglu N, Davies KD, Aisner DL, Devine WP. Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification. Modern Pathology. 2026. doi:10.1016/j.modpat.2026.101005

BibTeX
@article{Rabban2026,
  author = {Rabban, Joseph T and Wolsky, Rebecca J and Kayraklioglu, Neslihan and Davies, Kurtis D and Aisner, Dara L and Devine, W Patrick},
  title = {Copy Number-low/TP53-mutated Endometrial Cancer With Wild-type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next-generation Sequencing for Molecular Classification},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2026.101005}
}
Kostenlos starten →